Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
360 hedge funds and large institutions have $2.04B invested in Catalyst Pharmaceutical in 2025 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 129 increasing their positions, 134 reducing their positions, and 49 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
1.33% more ownership
Funds ownership: 83.09% → 84.42% (+1.3%)
0% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 49
4% less repeat investments, than reductions
Existing positions increased: 129 | Existing positions reduced: 134
1% less funds holding
Funds holding: 365 → 360 (-5)
7% less capital invested
Capital invested by funds: $2.2B → $2.04B (-$164M)
55% less call options, than puts
Call options by funds: $4M | Put options by funds: $8.84M
Top Buyers
| 1 |
DM
Deerfield Management
New York
|
+$43.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$19.1M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$15.8M |
| 4 |
Millennium Management
New York
|
+$15.4M |
| 5 |
Fundsmith LLP
London,
United Kingdom
|
+$13.5M |
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$28.9M |
| 2 |
Morgan Stanley
New York
|
-$27.6M |
| 3 |
BlackRock
New York
|
-$14.1M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$9.13M |
| 5 |
O
OrbiMed
New York
|
-$9.05M |
CPRX Hedge Fund Activity: Q3 2025 in Review
360 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2025, worth a combined $2.04B — down 7.4% from $2.2B a quarter earlier.
Fund positioning in CPRX was balanced in Q3 2025: 49 funds opened new positions, 49 closed out, 129 added to existing stakes and 134 trimmed.
The largest buyer was Deerfield Management, adding an estimated $43.1M. The largest seller was Goldman Sachs, cutting an estimated $28.9M.
- 360 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2025, down from 365 in Q2 2025.
- Funds reported $2.04B of Catalyst Pharmaceutical stock for Q3 2025, down 7.4% quarter-over-quarter.
- 49 funds opened new Catalyst Pharmaceutical positions in Q3 2025 and 49 closed out, a net change of 0 holders.
- The largest Catalyst Pharmaceutical buyer in Q3 2025 was Deerfield Management, an estimated $43.1M added.
- The largest Catalyst Pharmaceutical seller in Q3 2025 was Goldman Sachs, an estimated $28.9M sold.
Based on aggregated 13F filings for Q3 2025.